ERDERA Policy Brief: European Biotech Act

1:1
The European Rare Diseases Research Alliance (ERDERA), together with the European Reference Networks (ERNs), provides the missing operational layer required to implement the European Biotech Act across the full innovation pathway —from discovery to patient access.

This ERDERA policy brief frames rare diseases as a strategic test case for the proposed European Biotech Act, arguing that fragmented clinical, regulatory, and data ecosystems hinder translation from discovery to patient access. It identifies gaps in the draft Act (including limited recognition of existing infrastructures, narrow biotechnology scope, underdeveloped data frameworks, and skills shortages) and positions the combined ERDERA–European Reference Networks ecosystem as an operational backbone.

It provides seven policy recommendations spanning governance embedding, broader biotech definitions (including RNA, nanomedicine, and AI-enabled technologies), stronger interoperable data infrastructures, support for equitable multinational trials, skills initiatives, and improved investment conditions.

Acces this publication

publication

ERDERA Policy Brief

Year of publication

2026

Source

European Rare Diseases Research Alliance (ERDERA)

Author

You might also be interested in

Scientist reading a journal article 2026

Longitudinal progression, metrics, age-dependence, and modifiers of ataxia severity in SCA27B: a multicentre study of 219 patients

The multicentre observational study analysed 661 assessments from 219 people with SCA27B to examine disease progression, clinical outcome metrics and demographic or genetic modifiers.
Conference "Advancement of Treatments for Rare Diseases" in Cyprus, June 2026

Cyprus conference connects European research priorities with the path to rare disease treatments

At the “Advancement of Treatments for Rare Diseases” conference in Nicosia, European and national policymakers joined clinicians, researchers, regulators, industry representatives and patient advocates to examine how stronger coordination can translate scientific progress into better prevention, diagnosis, treatment and access to care for people living with rare diseases.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Call Text

Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.
ERDERA trainings template

ERDERA launches Ethics & Regulatory webinar series with introductory webinar on ethics across the research continuum

ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.

ERDERA's

search form